Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Absci Corp (ABSI)

Absci Corp (ABSI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Absci Corporation (ABSI) Reports Q3 Loss, Tops Revenue Estimates

Absci Corporation (ABSI) delivered earnings and revenue surprises of -11.11% and 32.72%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ABSI : 2.55 (unch)
SANG : 5.12 (+3.55%)
Cidara Therapeutics (CDTX) Q3 Earnings Miss Estimates

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -43.33% and 8.65%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

CDTX : 0.5581 (-5.09%)
ABSI : 2.55 (unch)
Absci Corporation (ABSI) Reports Q2 Loss, Misses Revenue Estimates

Absci Corporation (ABSI) delivered earnings and revenue surprises of 0% and 38.53%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ABSI : 2.55 (unch)
ALBO : 22.02 (-0.14%)
Aravive (ARAV) Reports Q2 Loss, Tops Revenue Estimates

Aravive (ARAV) delivered earnings and revenue surprises of 1.61% and 20.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ARAV : 1.4600 (-0.68%)
ABSI : 2.55 (unch)
Absci Reports Second Quarter 2022 Financial Results and Business Update

Exceeded annual Active Program guidance with ten programs signed year-to-date Executed strategic reorganization to extend cash runway into late-2025 ...

ABSI : 2.55 (unch)
The Zacks Analyst Blog Highlights Absci Axcella Health, Freeline Therapeutics Holdings, DICE Therapeutics and Pliant Therapeutics

Absci, Axcella Health, Freeline Therapeutics Holdings, DICE Therapeutics and Pliant Therapeutics are part of Zacks top Analyst Blog.

AXLA : 0.8739 (-0.85%)
PLRX : 17.97 (+4.60%)
FRLN : 0.5639 (-3.44%)
ABSI : 2.55 (unch)
DICE : 33.03 (-1.49%)
5 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.

AXLA : 0.8739 (-0.85%)
PLRX : 17.97 (+4.60%)
FRLN : 0.5639 (-3.44%)
ABSI : 2.55 (unch)
DICE : 33.03 (-1.49%)
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Misses Revenue Estimates

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -7.62% and 96.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

CRSP : 50.61 (-0.33%)
ABSI : 2.55 (unch)
Absci to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit Conference

VANCOUVER, Wash. and NEW YORK, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep...

ABSI : 2.55 (unch)
Absci to Participate in the SVB Securities CybeRx: Big Data, A.I. & Machine Learning in Healthcare Event

VANCOUVER, Wash. and NEW YORK, July 21, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep...

ABSI : 2.55 (unch)

Barchart Exclusives

Pre-Market Brief: Stocks Mixed As Rising Recession Worries Weigh On Sentiment
December S&P 500 futures (ESZ22) are trending up +0.08% this morning after three major US benchmark indices finished the regular session mixed as market participants weighed growing prospects of a recession associated with the pace of the Federal Reserve's monetary policy tightening. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar